Mark J. Selby

TL;DR: Blocking the PD-1 immune checkpoint with intermittent antibody dosing is well tolerated and associated with evidence of antitumor activity, and tumor cell surface B7-H1 expression appeared to correlate with the likelihood of response to treatment.

TL;DR: A strong synergy between the PD-1 and LAG-3 inhibitory pathways in tolerance to both self and tumor antigens is defined and it is argued strongly that dual blockade of these molecules represents a promising combinatorial strategy for cancer.

TL;DR: Data suggest that anti-CTLA-4 promotes antitumor activity by a selective reduction of intratumoral Tregs along with concomitant activation of Teffs.

TL;DR: In vitro assays demonstrated the ability of nivolumab to potently enhance T-cell responses and cytokine production in the mixed lymphocyte reaction and superantigen or cytomegalovirus stimulation assays, and no in vitro antibody-dependent cell-mediated or complement-dependent cytotoxicity was observed with the use of n ivolumAB and activated T cells as targets.

TL;DR: It is revealed that distinct Fcγ receptor (FcγRs) dependency and mechanisms account for the in vivo activity of anti- PD-1 versus anti-PD-L1 Abs, which show augmented anti-tumor activity when activating F cγR binding is introduced into the molecules.